Overview of the six original ACTIV-3/TICO trials. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Data from: Colony losses of stingless bees increase in agricultural areas, but decrease in forested areas حسب Malena Sibaja Leyton (18400983)

"…On average, meliponiculturists lost 43.4 % of their stingless bee colonies annually, 33.3 % during the rainy season, and 22.0 % during the dry season. We found that colony losses during the rainy season decreased with higher abundance of forested areas and increased with higher abundance of agricultural area around meliponaries. …"

Baseline patient characteristics. حسب Oscar F. C. van den Bosch (22184246)

"…In contrast, s-ketamine largely preserved respiratory variability, suggesting it may be a safer alternative for sedation in patients with impaired spontaneous breathing. …"

Ether Cleavage Decreases the Ion Exchange Capacity of Anion Exchange Membranes حسب Shakkira Erimban (6882539)

الموضوعات:

Ether Cleavage Decreases the Ion Exchange Capacity of Anion Exchange Membranes حسب Shakkira Erimban (6882539)

الموضوعات:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Long-term anti-nucleocapsid response by baseline patient characteristics. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Baseline patient characteristics across neutralizing monoclonal antibody trials. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Study Flow Diagram. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

nsP4-C483Y or Q192L mutations decrease sensitivity to 4′-FlU. حسب Peiqi Yin (6533747)